دورية أكاديمية
Broad-acting therapeutic effects of miR-29b-chitosan on hypertension and diabetic complications.
| العنوان: | Broad-acting therapeutic effects of miR-29b-chitosan on hypertension and diabetic complications. |
|---|---|
| المؤلفون: | Jensen DM; Department of Physiology, Center of Systems Molecular Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA., Han P; Department of Physiology, Center of Systems Molecular Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA; Department of Urology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu 210029, China., Mangala LS; Department of Gynecologic Oncology and Reproductive Medicine, UT MD Anderson Cancer Center, Houston, TX 77030, USA; Center for RNA Interference and Non-Coding RNA, UT MD Anderson Cancer Center, Houston, TX 77030, USA., Lopez-Berestein G; Center for RNA Interference and Non-Coding RNA, UT MD Anderson Cancer Center, Houston, TX 77030, USA; Department of Experimental Therapeutics, UT MD Anderson Cancer Center, Houston, TX 77030, USA., Sood AK; Department of Gynecologic Oncology and Reproductive Medicine, UT MD Anderson Cancer Center, Houston, TX 77030, USA; Center for RNA Interference and Non-Coding RNA, UT MD Anderson Cancer Center, Houston, TX 77030, USA., Liu J; Department of Physiology, Center of Systems Molecular Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA., Kriegel AJ; Department of Physiology, Center of Systems Molecular Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA., Usa K; Department of Physiology, Center of Systems Molecular Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA., Widlansky ME; Division of Cardiovascular Medicine, Department of Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA., Liang M; Department of Physiology, Center of Systems Molecular Medicine, Medical College of Wisconsin, Milwaukee, WI 53226, USA. Electronic address: mliang@mcw.edu. |
| المصدر: | Molecular therapy : the journal of the American Society of Gene Therapy [Mol Ther] 2022 Nov 02; Vol. 30 (11), pp. 3462-3476. Date of Electronic Publication: 2022 Aug 13. |
| نوع المنشور: | Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
| اللغة: | English |
| بيانات الدورية: | Publisher: Cell Press Country of Publication: United States NLM ID: 100890581 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1525-0024 (Electronic) Linking ISSN: 15250016 NLM ISO Abbreviation: Mol Ther Subsets: MEDLINE |
| أسماء مطبوعة: | Publication: 2017- : Cambridge, MA : Cell Press Original Publication: San Diego, CA : Academic Press, 2000- |
| مواضيع طبية MeSH: | MicroRNAs*/genetics , MicroRNAs*/metabolism , Chitosan* , Hypertension*/genetics , Hypertension*/therapy , Diabetes Complications* , Diabetes Mellitus*, Mice ; Humans ; Animals ; Angiotensin II/adverse effects ; Mice, Knockout, ApoE ; Disease Models, Animal ; Fibrosis ; Mice, Inbred Strains ; Thiolester Hydrolases |
| مستخلص: | MicroRNA miR-29 promotes endothelial function in human arterioles in part by targeting LYPLA1 and increasing nitric oxide production. In addition, miR-29 is a master inhibitor of extracellular matrix gene expression, which may attenuate fibrosis but could also weaken tissue structure. The goal of this study was to test whether miR-29 could be developed as an effective, broad-acting, and safe therapeutic. Substantial accumulation of miR-29b and effective knockdown of Lypla1 in several mouse tissues were achieved using a chitosan-packaged, chemically modified miR-29b mimic (miR-29b-CH-NP) injected systemically at 200 μg/kg body weight. miR-29b-CH-NP, injected once every 3 days, significantly attenuated angiotensin II-induced hypertension. In db/db mice, miR-29b-CH-NP treatment for 12 weeks decreased cardiac and renal fibrosis and urinary albuminuria. In uninephrectomized db/db mice, miR-29b-CH-NP treatment for 20 weeks significantly improved myocardial performance index and attenuated proteinuria. miR-29b-CH-NP did not worsen abdominal aortic aneurysm in ApoE knockout mice treated with angiotensin II. miR-29b-CH-NP caused aortic root fibrotic cap thinning in ApoE knockout mice fed a high-cholesterol and high-fat diet but did not worsen the necrotic zone or mortality. In conclusion, systemic delivery of low-dose miR-29b-CH-NP is an effective therapeutic for several forms of cardiovascular and renal disease in mice. Competing Interests: Declaration of interests The authors declare no competing interests. (Copyright © 2022 The American Society of Gene and Cell Therapy. Published by Elsevier Inc. All rights reserved.) |
| References: | Curr Drug Deliv. 2013 Oct;10(5):493-9. (PMID: 23410069) Indian Heart J. 2016 Jan-Feb;68(1):83-7. (PMID: 26896273) EBioMedicine. 2018 Sep;35:260-269. (PMID: 30120082) Hypertension. 2008 Apr;51(4):899-904. (PMID: 18316652) EMBO Mol Med. 2018 Mar;10(3):. (PMID: 29374012) Hypertension. 2015 Oct;66(4):793-9. (PMID: 26283043) J Am Coll Cardiol. 2003 Oct 1;42(7):1149-60. (PMID: 14522472) Eur Heart J. 2004 Dec;25(24):2220-5. (PMID: 15589639) Eur Heart J. 2000 Nov;21(22):1888-95. (PMID: 11052862) EMBO Mol Med. 2014 Sep 19;6(10):1347-56. (PMID: 25239947) J Clin Invest. 2012 Jun;122(6):1973-90. (PMID: 22622040) JAMA. 2016 Jan 26;315(4):343-4. (PMID: 26769233) Oncotarget. 2015 Oct 6;6(30):29161-77. (PMID: 26313360) Physiol Genomics. 2012 Feb 27;44(4):237-44. (PMID: 22214600) Hypertension. 2003 May;41(5):1012-5. (PMID: 12682080) J Am Soc Nephrol. 2018 Oct;29(10):2518-2528. (PMID: 30049682) Hepatology. 2011 Jan;53(1):209-18. (PMID: 20890893) J Clin Invest. 2007 Sep;117(9):2369-76. (PMID: 17786230) Hypertension. 2019 Feb;73(2):399-406. (PMID: 30595117) Lancet. 2020 Oct 17;396(10258):1223-1249. (PMID: 33069327) Nephrol Dial Transplant. 2010 Jun;25(6):1811-7. (PMID: 20067909) Nat Rev Drug Discov. 2017 Mar;16(3):203-222. (PMID: 28209991) Lab Anim (NY). 2011 May;40(5):155-60. (PMID: 21508954) PLoS Biol. 2018 Oct 22;16(10):e2006247. (PMID: 30346946) N Engl J Med. 2013 Jun 27;368(26):2531-2. (PMID: 23802533) Acta Physiol Scand. 2004 Aug;181(4):585-92. (PMID: 15283774) Cancer Cell. 2010 Aug 9;18(2):185-97. (PMID: 20708159) Kidney Int. 2022 Apr;101(4):766-778. (PMID: 35114200) EMBO Mol Med. 2016 Jun 01;8(6):643-53. (PMID: 27137489) J Biol Chem. 2018 Sep 7;293(36):14080-14088. (PMID: 30006350) Circulation. 1994 Jul;90(1):479-83. (PMID: 8026034) J Am Soc Nephrol. 2012 Nov;23(11):1810-23. (PMID: 22997257) J Am Soc Nephrol. 2006 Oct;17(10):2664-9. (PMID: 16971655) J Am Soc Nephrol. 2020 Jul;31(7):1539-1554. (PMID: 32487559) Am J Pathol. 2010 Mar;176(3):1079-83. (PMID: 20075197) J Am Soc Echocardiogr. 2003 Aug;16(8):814-23. (PMID: 12878990) Nature. 2014 Aug 28;512(7515):431-5. (PMID: 25043055) J Clin Invest. 2012 Feb;122(2):497-506. (PMID: 22269326) Hypertension. 2018 Nov;72(5):1160-1171. (PMID: 30354815) J Am Soc Nephrol. 2011 Aug;22(8):1462-74. (PMID: 21784902) Nucleic Acids Res. 2013 Jan;41(2):1273-83. (PMID: 23221637) Circ Res. 2014 Jan 3;114(1):32-40. (PMID: 24084690) Mol Ther. 2006 Oct;14(4):476-84. (PMID: 16829204) Clin Cancer Res. 2010 Aug 1;16(15):3910-22. (PMID: 20538762) Hypertension. 2010 Apr;55(4):974-82. (PMID: 20194304) Proc Natl Acad Sci U S A. 2008 Sep 2;105(35):13027-32. (PMID: 18723672) Physiol Genomics. 2009 Jul 9;38(2):113-5. (PMID: 19470802) Circ Res. 2012 Jan 20;110(2):312-24. (PMID: 22116819) Hypertension. 2001 Feb;37(2 Pt 2):456-61. (PMID: 11230318) Nat Commun. 2013;4:2427. (PMID: 24018975) Arterioscler Thromb Vasc Biol. 2007 Jan;27(1):77-83. (PMID: 17068286) Mol Ther. 2014 Apr;22(4):842-53. (PMID: 24445937) Mol Ther Nucleic Acids. 2017 Sep 15;8:132-143. (PMID: 28918016) |
| معلومات مُعتمدة: | P01 HL149620 United States HL NHLBI NIH HHS; P01 HL116264 United States HL NHLBI NIH HHS; R01 HL121233 United States HL NHLBI NIH HHS; T32 HL134643 United States HL NHLBI NIH HHS; P01 GM066730 United States GM NIGMS NIH HHS; R01 HL125409 United States HL NHLBI NIH HHS |
| فهرسة مساهمة: | Keywords: albuminuria; aneurysm; atherosclerosis; diabetic complications; fibrosis; heart; hypertension; kidney; microRNA; therapeutics |
| المشرفين على المادة: | 11128-99-7 (Angiotensin II) 0 (MicroRNAs) 9012-76-4 (Chitosan) EC 3.1.2.- (Lypla1 protein, mouse) EC 3.1.2.- (Thiolester Hydrolases) 0 (MIRN29 microRNA, mouse) |
| تواريخ الأحداث: | Date Created: 20220815 Date Completed: 20221107 Latest Revision: 20240613 |
| رمز التحديث: | 20240613 |
| مُعرف محوري في PubMed: | PMC9637778 |
| DOI: | 10.1016/j.ymthe.2022.08.007 |
| PMID: | 35965413 |
| قاعدة البيانات: | MEDLINE |
كن أول من يترك تعليقا!